Boni, Valentina
Hospital Universitario Quirónsalud Madrid · IDCQ Hospitales y Sanidad, S.L.U.
6 papers on CoChatORCID 0000-0002-8675-0018
Most cited papers
- Verified
Efficacy of Larotrectinib in TRK Fusion–Positive Cancers in Adults and Children
Drilon, A., Laetsch, T. W., Kummar, S., DuBois, S. G., Lassen, U. N., Demetri, G. D., Nathenson, M., Doebele, R. C., Farago, A. F., Pappo, A. S., et al. (2018) · New England Journal of Medicine
Sarcoma Diagnosis and TreatmentCancer Genomics and Diagnostics
Cited by 2,824
- Verified
HER kinase inhibition in patients with HER2- and HER3-mutant cancers
Hyman, D. M., Piha-Paul, S. A., Won, H., Rodon, J., Saura, C., Shapiro, G. I., Juric, D., Quinn, D. I., Moreno, V., Doger, B., et al. (2018) · Nature
HER2/EGFR in Cancer ResearchLung Cancer Treatments and Mutations
Cited by 780
- Verified
Tipifarnib in Head and Neck Squamous Cell Carcinoma With HRAS Mutations
Ho, A. L., Brana, I., Haddad, R., Bauman, J., Bible, K., Oosting, S., Wong, D. J., Ahn, M.-J., Boni, V., Even, C., et al. (2021) · Journal of Clinical Oncology
Head and Neck Cancer StudiesLung Cancer Treatments and Mutations
Cited by 208
- Verified
Phase I, First-in-Human Study of the Probody Therapeutic CX-2029 in Adults with Advanced Solid Tumor Malignancies
Johnson, M., El-Khoueiry, A., Hafez, N., Lakhani, N., Mamdani, H., Rodon, J., Sanborn, R. E., Garcia-Corbacho, J., Boni, V., Stroh, M., et al. (2021) · Clinical Cancer Research
Monoclonal and Polyclonal Antibodies ResearchCancer Immunotherapy and Biomarkers
Cited by 72
- Verified
Abstract PR014: Preliminary safety and anti-tumor activity of RMC-6291, a first-in-class, tri-complex KRASG12C (ON) inhibitor, in patients with or without prior KRASG12C (OFF) inhibitor treatment
Jänne, P. A., Bigot, F., Papadopoulos, K., Eberst, L., Sommerhalder, D., Lebellec, L., Voon, P. J., Pellini, B., Kalinka, E., Arbour, K., et al. (2023) · Molecular Cancer Therapeutics
Protein Kinase Regulation and GTPase SignalingLung Cancer Treatments and Mutations
Cited by 63
- Verified
CX-072 (pacmilimab), a Probody PD-L1 inhibitor, in combination with ipilimumab in patients with advanced solid tumors (PROCLAIM-CX-072): a first-in-human, dose-finding study
Sanborn, R. E., Hamid, O., de Vries, E. G., Ott, P. A., Garcia-Corbacho, J., Boni, V., Bendell, J., Autio, K. A., Cho, D. C., Plummer, R., et al. (2021) · Journal for ImmunoTherapy of Cancer
Cancer Immunotherapy and BiomarkersImmunotherapy and Immune Responses
Cited by 28
Go further with a free account
Verify every reference, keep papers in a library, and ask questions across them.
Sign up - it is free